Enhance virotherapy efficacy and safety with precision-engineered, breast cancer-specific adenoviral vectors. Overcome off-target liver toxicity and maximize tumor lysis, immunomodulation, and therapeutic transgene expression in HER2+, ER/PR+, and triple-negative breast cancer (TNBC) models.
Precision Targeting for Breast Cancer Gene Therapy
Breast cancer remains one of the most prevalent malignancies globally, necessitating advanced, highly specific therapeutic platforms. Adenoviral vectors, particularly conditionally replicating adenoviruses (CRAds), offer immense potential for oncolytic virotherapy and localized gene delivery. However, conventional adenoviral vectors face challenges such as poor transduction of tumor cells lacking primary receptors and unwanted sequestration in the liver. Creative Biolabs provides custom breast cancer-targeting adenovirus vector construction, utilizing sophisticated transcriptional and transductional targeting strategies to restrict viral activity to the tumor microenvironment (TME) and improve therapeutic indices.
Transcriptional Targeting
We integrate tumor-specific promoters (TSPs) such as MUC1, hTERT, Survivin, or CXCR4 into the adenoviral backbone. This restricts viral replication or therapeutic gene expression entirely to breast cancer cells, preventing off-target toxicity in healthy tissues like the liver and spleen.
Transductional Targeting
By genetically modifying the adenoviral capsid—specifically the fiber knob or hexon proteins—we bypass natural CAR (Coxsackievirus and Adenovirus Receptor) dependency and insert tumor-homing ligands (e.g., against EGFR, HER2, or integrins), drastically increasing uptake in malignant cells.
Enhanced Safety & Potency
The dual-targeting approach minimizes systemic toxicity and maximizes localized oncolysis or transgene expression. This enables synergistic combinations with immune checkpoint inhibitors, chemotherapy, or radiation, unlocking higher, safer dosing regimens.
Our Custom Construction Services
Transcriptional Targeting via Tumor-Specific Promoters
We help clients select and integrate highly efficient tumor-specific regulatory elements to ensure viral replication or transgene expression is isolated to the breast tumor microenvironment.
Mucin 1 (MUC1) and ERBB2 (HER2) are frequently overexpressed in various breast cancer subtypes. We utilize optimized MUC1 or ERBB2 promoter cassettes to drive E1A/E1B expression, creating potent, conditionally replicating adenoviruses (CRAds).
Telomerase reverse transcriptase (hTERT) and survivin promoters are highly active in the vast majority of human carcinomas, including TNBC. They offer robust tumor-on capabilities while remaining stringently silent in normal somatic cells.
To target the hypoxic core of solid breast tumors, we engineer synthetic promoters incorporating Hypoxia-Inducible Factor (HIF) binding sites, ensuring maximum therapeutic payload delivery precisely where conventional therapies fail.
Transductional Targeting via Capsid Modification
Breast cancer cells frequently downregulate CAR, rendering standard Ad5 vectors inefficient. By altering the adenoviral capsid, we force viral entry through tumor-associated antigens, overcoming resistance and preventing liver accumulation.
We mutate the native binding sites on the viral fiber knob, ablating liver tropism. We then genetically insert ligands, such as RGD motifs or affibodies (e.g., targeting HER2 or EGFR), directly into the capsid to actively retarget the virus to the tumor surface.
We construct chimeric vectors substituting the Ad5 fiber knob with that of Ad3 or Ad35. These chimeras utilize CD46 or desmoglein-2 receptors—which are highly expressed on many breast cancer cells—dramatically enhancing infectivity compared to native Ad5.
We can also develop bi-specific adapter molecules (e.g., scFv-sCAR fusions) that bridge the native adenovirus particle directly to breast cancer-specific markers, offering a highly flexible retargeting strategy without altering the viral genome.
Advanced Adenoviral Vector Backbones
Creative Biolabs utilizes versatile adenoviral platforms tailored to your therapeutic strategy, whether you are developing direct oncolytic agents or immunomodulatory gene therapies.
The premier choice for oncolytic virotherapy. We engineer the E1 gene under the control of a breast tumor-specific promoter. The virus specifically replicates in, and lyses, tumor cells, subsequently spreading to adjacent malignant tissues.
We further "arm" CRAds with therapeutic transgenes (such as IL-12, GM-CSF, or bispecific T-cell engagers) inserted into the E3 region, amplifying the anti-tumor immune response within the TME following oncolysis.
Ideal for high-level, localized expression of immunomodulators, suicide genes (e.g., HSV-TK for GDEPT), or anti-angiogenic factors without the complexities of viral replication. Accommodates up to ~8 kb of genetic payload.
Tumor-Targeted AdV vs. Other Delivery Systems
See how our engineered, breast cancer-targeted adenoviral vectors compare to standard alternatives in the context of oncology.
| Feature | Standard Adenovirus (Ad5) | Breast Cancer-Targeted Adenovirus | Lentiviral Vectors |
|---|---|---|---|
| Primary Tropism (Systemic) | Liver (Hepatocytes) | Breast Tumor Microenvironment | Broad (dependent on envelope pseudotype) |
| Oncolytic Capability | Yes | Yes, Highly Potent and Tumor-Specific | No (Replication Defective) |
| CAR-Receptor Dependency | High (Poor efficacy in CAR-low tumors) | None (Bypassed via capsid engineering) | N/A |
| Immunogenicity | High (rapidly cleared) | Harnessed for "In Situ" Vaccination | Low to Moderate |
| Best Use Case in Oncology | In vitro assays, basic research | Solid tumor destruction, TME immune priming | Ex vivo cell engineering (e.g., CAR-T) |
Production & Quality Control Capabilities
Comprehensive platforms for the production and rigorous testing of targeted adenoviral vectors, ensuring high-titer, high-purity particles for translational oncology.
Scalable Production & Purification
Our dedicated viral production facilities ensure that your tumor-targeted vectors are packaged, amplified, and purified to the highest industry standards, ready for in vivo tumor modeling.
-
Scale-Up Production Using optimized HEK293 suspension or adherent culture systems, we can scale up vector production to meet any requirement, from small-scale pilot studies to large-batch animal trials.
-
Advanced Purification Vectors undergo rigorous downstream processing, utilizing double Cesium Chloride (CsCl) gradient ultracentrifugation to achieve high purity (>95%) and remove empty capsids, host cell proteins, and DNA.
Comprehensive Release Testing
Rigorous testing ensures the physical titer, infectious titer, purity, and safety of the final viral vector products. Each batch is supplied with a comprehensive Certificate of Analysis (CoA).
| Parameter | Specification | Assay |
|---|---|---|
| Physical Titer (VP/mL) | > 10¹² VP/mL | OD260 Measurement / qPCR |
| Infectious Titer (IFU/mL) | > 10¹⁰ IFU/mL | TCID50 Assay / Plaque Assay |
| Purity & Capsid Integrity | > 95% intact capsids | SDS-PAGE / Western Blotting |
| Endotoxin | < 5 EU/mL | LAL Chromogenic Assay |
| Sterility | No growth | 14-day bacterial/fungal culture |
Applications in Oncology
Harnessing conditionally active adenoviruses unlocks therapeutic potential across various modalities of breast cancer treatment.
| Application Area | Mechanism | Specific Examples |
|---|---|---|
| Oncolytic Virotherapy | Selective viral replication leads to targeted tumor cell lysis, releasing tumor-associated antigens (TAAs) and inducing immunogenic cell death. | Treating advanced Triple-Negative Breast Cancer (TNBC) using hTERT-driven CRAds engineered with Ad5/3 chimeric fibers. |
| Immune Priming (Armed CRAds) | Localized production of cytokines or immune stimulators transforms a "cold" tumor microenvironment into a "hot" one, synergistic with immune checkpoint blockade. | Expression of IL-12, GM-CSF, or CD40L directly within the solid tumor mass, minimizing systemic cytokine storm risks. |
| Gene-Directed Enzyme Prodrug Therapy (GDEPT) | Delivery of an enzyme that converts a systemically administered, non-toxic prodrug into a highly toxic chemotherapeutic agent exclusively within the tumor. | Delivery of HSV-TK followed by systemic ganciclovir administration, localized to HER2+ breast cancer cells. |
Case Study: Dual-Targeted CRAd for TNBC
A demonstration of overcoming receptor deficiency and systemic toxicity using precision viral engineering.
Background: Triple-Negative Breast Cancer (TNBC) lacks ER, PR, and HER2 expression, limiting targeted therapy options. Furthermore, TNBC cells often exhibit low CAR expression, making them resistant to standard Ad5-based gene delivery.
Approach: Creative Biolabs designed a dual-targeted Conditionally Replicating Adenovirus (CRAd). Transcriptional targeting was achieved by placing the adenoviral E1A gene under the control of a tumor-specific CXCR4 promoter, highly active in metastatic TNBC. Transductional targeting was achieved by replacing the native Ad5 fiber knob with an Ad5/3 chimeric fiber, bypassing CAR and utilizing desmoglein-2 for highly efficient cell entry.
Results: In a murine orthotopic TNBC xenograft model, the engineered Ad5/3-CXCR4 CRAd demonstrated massive intra-tumoral viral replication and spread. CAR-deficient tumor cells were effectively transduced, leading to significant tumor regression and prolonged survival compared to control groups. Importantly, off-target viral accumulation in the liver was profoundly minimized due to the stringency of the CXCR4 promoter.
Conclusion: This case highlights the necessity and efficacy of combining capsid retargeting with tumor-specific promoters to safely and effectively treat refractory malignancies like TNBC.
Why Choose Creative Biolabs for Virotherapy?
We provide an end-to-end, highly customizable platform that addresses the most critical bottlenecks in oncolytic virus development.
Enhanced Safety
Dual targeting (transcriptional + transductional) drastically minimizes hepatotoxicity, confining viral activity exclusively to the malignant tissue.
High Oncolytic Potency
Bypassing CAR deficiency via fiber chimeras ensures robust viral entry, leading to superior viral burst sizes and profound tumor lysis.
Total Customization
From selecting the ideal cancer-specific promoter to arming the virus with immunomodulatory cytokines, your vector is tailored to your strategy.
Preclinical Grade
Rigorous CsCl purification and comprehensive QC (titer, purity, endotoxin) guarantee oncolytic vectors ready for immediate in vivo use.
Our Construction Workflow
A systematic, quality-driven process from in-silico design to ready-to-use viral particles.
1. Design & Strategy Consultation
Our Ph.D.-level virologists and oncologists work with you to select the optimal combination of vector backbone (CRAd vs. Deficient), tumor-specific promoter, and capsid modifications based on your specific breast cancer target.
2. Plasmid Construction & Sequence Verification
We synthesize your targeting cassettes and transgenes, cloning them into customized shuttle plasmids. Recombinant adenoviral genomes are generated via homologous recombination in E.coli. All critical regions are verified by Sanger sequencing.
3. Packaging, Amplification & Release
The recombinant genome is transfected into appropriate complementing cell lines for viral rescue. Plaques are isolated and amplified. The crude viral lysate is then subjected to stringent purification to yield research- or preclinical-grade vector stocks with a full Certificate of Analysis (CoA).
Frequently Asked Questions
Plan Your Vector Construction
To help us provide an accurate quote quickly, please consider the following details:
- Disease Target: Breast Cancer subtype (e.g., HER2+, TNBC, ER+).
- Promoter Choice: Standard (CMV) or Tumor-specific (MUC1, hTERT, Survivin, etc.).
- Vector System: Conditionally Replicating (CRAd) or Replication-deficient (E1/E3 deleted).
- Capsid Modification: Native Ad5, Fiber Chimeras (Ad5/3), or specific peptide insertions.
- Delivery Scale: Required physical titer (VP/mL), infectious titer (IFU/mL), and volume for preclinical studies.
Get Your Custom Quote
Our virology experts are ready to design the optimal breast cancer-targeting adenoviral vector for your research. Fill out the inquiry form below with your project details, and we will respond within 24-48 hours.
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
